NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Drug Manufacturers - General · USD

Novo Nordisk A/S (NVO) Stock Analysis

Novo Nordisk A/S (NVO) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

NVO

$39.06

−$0.29 (−0.74%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NVO with… →

NVO Key Statistics

As of Oct 21, 2026
Trading
Open
$39.25
Previous Close
$39.35
Day's Range
39.05–39.49
52-Week Range
35.12–64.16
Volume
6.72M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.38
Valuation
Market Cap
$172.38B
P/E Ratio
9.55
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
11.46
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
4.40
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.52
EPS (ttm)Profit attributable to each share over the last twelve months.
4.09
Financials (FY)
Revenue (FY)
$309.06B+6.43%
Net Income (FY)
$102.43B+1.43%
Profit marginThe share of revenue left as profit after all costs and taxes.
35.35%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.34B
1-Year Return
−26.08%
Dividend and dates
Dividend
$1.80+4.57%
Ex-Dividend Date
August 17, 2026
Earnings Date
November 4, 2026
Avg Volume
12.89M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NVO closed at $39.06, −26.08% over 1 year.

Novo Nordisk A/S (NVO) has a market capitalization of $172.38B.

In fiscal 2025, NVO reported revenue of $309.06B.

NVO Stock Return by Calendar Year

Novo Nordisk A/S (NVO) 10-year return: what $10,000 became

1 year
$10,000 $7,392
−26.08%
5 years
$10,000 $8,284
−17.16%
10 years
$10,000 $23,477
+134.77%

If you had invested $10,000 in Novo Nordisk A/S (NVO) 10 years ago, at the close on October 21, 2016, it would have been worth $23,477 at the close on October 21, 2026: +134.77% in total, +8.91% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−20.42%
2025−39.22%
2024−15.94%
2023+54.84%
2022+22.66%
2021+63.52%
2020+23.33%
2019+28.70%
2018−12.12%
2017+54.23%
2016 (partial year)−23.19%

As of October 21, 2026.

NVO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$309.06B$102.43B33.1%
2024$290.40B$100.99B34.8%
2023$232.26B$83.68B36.0%
2022$176.95B$55.53B31.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$309.06B$250.28B$127.66B$102.43B33.1%
2024$290.40B$245.88B$128.34B$100.99B34.8%
2023$232.26B$196.50B$102.57B$83.68B36.0%
2022$176.95B$148.51B$74.81B$55.53B31.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NVO Dividend History

$1.68+16.6% vs 2024

Dividends per share, 2025 · 2 payments

YearDividends per sharePaymentsChange
2026*$1.852—
2025$1.682+16.6%
2024$1.442+39.2%
2023$1.042+28.0%
YearDividends per sharePaymentsChange
2026 (partial year)$1.852—
2025$1.682+16.6%
2024$1.442+39.2%
2023$1.042+28.0%
2022$0.812+7.6%
2021$0.752+15.4%
2020$0.652+5.4%
2019$0.622+8.9%
2018$0.572+0.0%
2017$0.572—

Most recent payment: $0.93 per share, ex-dividend August 17, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

NVO Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricNVODrug Manufacturers - General medianvs median
P/E9.5525.2362% below
P/S ratio0.523.230.2x the median
Profit margin35.35%9.80%25.5 pts above

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Novo Nordisk A/S (NVO) at $172.38B. The company sits in the Healthcare sector, in the Drug Manufacturers - General industry. Headcount on file is 66,700.

NVO last closed at $39.06 on October 21, 2026. That is −$0.29 (−0.74%) against the previous close. Over the past 52 weeks the price has ranged from $35.12 to $64.16. The latest close sits 11.22% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $309.06B. That is +6.43% against the prior fiscal year, when revenue was $290.40B. Net income for the same year was $102.43B. That is +1.43% against the prior fiscal year. Profit margin runs at 35.35%. That is 25.5 percentage points above the Drug Manufacturers - General median of 9.8%. Trailing earnings per share are 4.09.

Across the 4 fiscal years on file, revenue moves from $176.95B in 2022 to $309.06B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 9.55 times earnings. That is 62.15% below the Drug Manufacturers - General median of 25.23. On forward earnings the ratio is 11.46. The PEG ratio, which sets the P/E against expected earnings growth, reads 4.4. The price-to-sales ratio is 0.52. On price-to-sales that is 0.2 times the Drug Manufacturers - General median of 3.23. 21 Drug Manufacturers - General companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −26.08%. Across 10 years the annualized return works out at +8.91%. The reported beta is 0.38. Annualized volatility over the trailing 10 years is 32.81%.

Growth & Income

Shareholders receive a dividend, yielding 4.57% on the latest price. That is 2.3 percentage points above the Drug Manufacturers - General median yield of 2.3%. At the indicated rate that is $1.80 a share a year. The ex-dividend date on file is August 17, 2026. Dividends are recorded for 10 calendar years; 2026 shows 2 payments totalling $1.85 a share. The year before, 2025, totalled $1.68 a share.

So far in 2026 the total return is −20.42%. Across the complete calendar years on file, 2021 returned +63.52% and 2025 returned −39.22%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Novo Nordisk A/S (NVO) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Novo Nordisk A/S NVO $172.38B 9.6
Eli Lilly and Company LLY $1.13T 42.7
Johnson & Johnson JNJ $621.22B 39.1
AbbVie Inc. ABBV $503.27B 80.5

The Drug Manufacturers - General industry average P/E ratio is 25.2x. Novo Nordisk A/S trades at a P/E of 9.6.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 MRK

Merck & Co., Inc.

$369.78B

 NVS

Novartis AG

$292.58B

 AZN

AstraZeneca PLC

$261.82B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$374.30B

 TMO

Thermo Fisher Scientific Inc.

$256.61B

 AMGN

Amgen Inc.

$236.98B

 GILD

Gilead Sciences, Inc.

$190.42B

 ABT

Abbott Laboratories

$173.92B
View all Healthcare stocks →

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Visit website →